8-K
filed February 11, 2026, 6:59 PM ET
ticker INSP
CIK 0001609550
earnings
confidence high
sentiment negative
materiality 0.85
Inspire Q4 rev $269M (+12%), EPS $4.66; FY26 outlook lowered on coding change
Inspire Medical Systems, Inc.
2025-FY EPS reported
$4.89
revenue$911,981,000
- Q4 revenue $269.1M (+12%); GAAP diluted EPS $4.66; adjusted EPS $1.65.
- Full year revenue $912M (+14%); operating cash flow $117M; share repurchases $175M.
- FY2026 revenue guidance revised to $950M-$1.0B (4-10% growth); adjusted EPS $1.85-$2.35.
- Inspire V procedure coding changed to CPT 64582 with -52 modifier, reducing physician fees; company disappointed.
- Board proposes declassification and removal of for-cause removal; effective upon shareholder approval at 2026 annual meeting.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Inspire Medical Systems, Inc.: Proposal to declassify the Board of Directors and provide for annual election of directors following a phase-in period, subject to stockholder approval at the 2026 Annual Meeting.
- Change
- charter amendment
Exact text from the filing
The Company intends to put forth a proposal at the Company’s annual meeting of stockholders to be held in 2026 (the “2026 Annual Meeting”) to amend its Seventh Amended and Restated Certificate of Incorporation in order to declassify its Board of Directors (the “Board”) and provide for the annual election of directors following a phase-in period (the “Proposed Charter Amendment”).
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Inspire Medical Systems, Inc.: Amended and Restated Bylaws approved by the Board, subject to and effective upon stockholder approval of the Proposed Charter Amendment, removing the provision that directors may be removed only for cause (effective 2026-02-05).
- Change
- bylaw amendment
- Effective
- 2026-02-05
Exact text from the filing
On February 5, 2026, the Board approved the Amended and Restated Bylaws of the Company (the “Amended Bylaws”), subject to and effective upon the approval of the Proposed Charter Amendment by the stockholders at the Company’s 2026 Annual Meeting.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.